5 min read
Highlights
Precision fermentation is no longer just a startup experiment: it’s becoming a question of industrial capability.
- Dairy is splitting into two production systems: One is built around cows, land and feed. The other is built around microorganisms, fermentation capacity, data and bioprocessing.
- The commercial signal is strengthening: Partnerships involving Perfect Day, Novonesis, TurtleTree, Bel Group, Standing Ovation, Formo and Those Vegan Cowboys show that scale is becoming the central challenge.
- The limitations remain real: Regulatory approval varies by market, costs remain unresolved and commercial targets aren’t the same as commercial success.
- The strategic question is changing: Dairy leaders need to decide whether they’ll control, access or partner for the second factory.
Precision fermentation dairy is moving from startup experimentation towards industrial strategy.
In simple terms, precision fermentation uses microorganisms as tiny production factories to make specific proteins. Instead of relying on a cow to produce whey, casein or lactoferrin, companies programme a microorganism to produce the target protein inside a controlled fermentation system. This is a direct expression of my TECHXponential™ model technology, Synthetic Biology, with strong connections to Alternative Proteins, Cellular Agriculture, Microbiome science and Genomics.
Dairy isn’t disappearing. It’s splitting into two production systems — one built around animals, land and feed, and another built around microbes, fermentation capacity, data and industrial bioprocessing.
I believe the second factory will become one of the defining competitive platforms of the next dairy era. It won’t replace farms. It will sit alongside them, producing specific proteins with greater control over functionality, supply, nutrition and resource use. The companies that understand how to connect both systems will have more options than those that defend only one.
The current signal
The clearest signal is the movement from laboratory proof to planned commercial capacity.
Perfect Day’s planned Gujarat facility is targeting initial operations in 2026, first commercial deliveries of recombinant whey in 2027 and reported first-year production of 2,000 metric tonnes. They are still company targets, but they show the scale of ambition now entering the market.
The partnership between TurtleTree and Novonesis sends an equally important signal. TurtleTree brings its lactoferrin technology, while Novonesis contributes industrial manufacturing and global commercial capability.
Lactoferrin is especially significant because it sits at the convergence of food and health. It’s being developed for early-life nutrition and selected applications in dietary supplements, sports nutrition, medical nutrition and gut health. Its value comes partly from the difficulty of extracting meaningful quantities from conventional milk.
Investment is also returning. Standing Ovation’s casein scale-up reflects renewed interest in fermentation-derived dairy proteins after a period when investors became more cautious about food technology.
Meanwhile, Formo and Those Vegan Cowboys are advancing precision-fermented casein towards the US market after progress through the FDA GRAS process. Casein matters because it provides the structure, melt, stretch, emulsification and gelation that make many dairy products work.
Wageningen researchers have also reported a scalable process for synthetic dairy proteins. Together, these developments suggest that the question is shifting from whether the science works to whether this second production system can work economically.
Technical proof + industrial partnerships = the beginning of a second dairy factory.
The present limitation
Scale still matters.
A company can produce a protein in a laboratory and then face a harder challenge in a large fermenter. It must purify the protein, manage energy and feedstock costs, maintain quality, secure customers and navigate regulation.
Regulation is progressing, but not at the same speed everywhere. Costs are still being worked through, especially in fermentation capacity and downstream processing. Consumer trust matters too, because taste, functionality and communication all shape adoption across clear protein drinks, infant nutrition and cheese.
The industry has learned an important lesson. Sustainability helps, but supply security, performance, nutrition and price may be even stronger commercial drivers.
Regulatory capability + cost discipline + consumer trust = the real test of scale.
The future possibility
I believe the future dairy industry will use both production systems.
Conventional dairy will continue for milk, cheese, whey and other products where the economics, consumer expectations and supply chains already work. Fermentation-derived proteins will grow where they solve specific problems, including ingredient shortages, functionality gaps, supply volatility and the need for highly targeted nutrition.
By 2035 to 2040, the second factory could give dairy companies a far more flexible production model. Fermentation capacity, biological data and AI-enabled process control could help produce proteins for cheese, infant nutrition, sports nutrition, medical nutrition and gut-health products closer to demand. That would mean more control over functionality, faster response to supply disruption and a stronger ability to direct specialised proteins into higher-value markets.
Interestingly a second, complementary approach is emerging through cellular mammary gland agriculture. Instead of only programming microorganisms to make individual dairy proteins, some companies are growing mammary cells directly in bioreactors to produce milk components such as casein, whey and milk fats. This is cellular agriculture applied to milk itself. Helaina is already producing human lactoferrin at commercial scale through large-scale fermentation, with a strategic partnership with Nestlé for early-life nutrition and infant nutrition applications. 108Labs is developing a cell-cultured milk platform using mammary cells and a turnkey hardware, software and AI stack, with the stated ambition of cell-cultured milk replacing conventional bovine milk by 2040. BIOMILQ announced in 2026 that it has successfully produced cell-cultured human milk by growing the cells under conditions that mimic the environment inside the breast, so they behave as they would in the body and produce milk components. This could become an important extension of the second factory, especially where application-specific dairy functionality becomes a source of strategic value, although producing whole milk from cells is more complex than producing individual proteins, and cost, scale and regulatory approval are still being worked through.
This is why precision fermentation dairy shouldn’t be viewed simply as another alternative product category. It’s a new manufacturing platform.
The strategic implication for dairy leaders
For Boards and C-suite teams, the question is no longer whether precision fermentation threatens dairy. The strategic question is whether your organisation will own, access or partner for fermentation capacity, and whether it can integrate animal agriculture, bioprocessing, data and consumer trust into one portfolio strategy.
Leaders should consider five questions.
- Does our long-term ingredient portfolio depend on proteins that could face supply or price pressure?
- Do we have access to fermentation capacity, downstream processing and the specialist talent required to use it?
- Should we build, buy or partner rather than waiting for the market to mature?
- Can our regulatory and quality systems support products made through new biological processes?
- How will we explain these ingredients to consumers while protecting trust in the dairy category?
The first factory will continue to depend on cows, farms and land. The second will depend on microbes, fermentation capacity, biological data and industrial bioprocessing. The future winners will connect both systems rather than choose between them.
Dairy leadership + biological manufacturing capability = a more resilient and more adaptable food system.
The second factory isn’t a threat waiting outside the dairy industry. It’s a capability the industry needs to start building.
To continue the conversation email me at tony@tonyhunterspeaker.com